CD86<sup>+</sup>or HLA-G<sup>+</sup> can be transferred via trogocytosis from myeloma cells to T cells and are associated with poor prognosis
Brown, R
Kabani, K
Favaloro, J
Yang, S
Ho, PJ
Gibson, J
Fromm, P
Suen, H
Woodland, N
Nassif, N
Hart, D
Joshua, D
Hart, D
Joshua, D
- Publication Type:
- Journal Article
- Citation:
- Blood, 2012, 120 (10), pp. 2055 - 2063
- Issue Date:
- 2012-09-06
Closed Access
| Filename | Description | Size | |||
|---|---|---|---|---|---|
 | 2011008408OK.pdf | 536.63 kB |
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
The transfer of membrane proteins between cells during contact, known as trogocytosis, can create novel cells with a unique phenotype and altered function. We demonstrate that trogocytosis is more common in multiple myeloma (MM) than chronic lymphocytic leukemia and Waldenstrom macroglobulinaemia; that T cells are more probable to be recipients than B or natural killer cells; that trogocytosis occurs independently of either the T-cell receptor or HLA compatibility; and that after trogocytosis, T cells with acquired antigens can become novel regulators of T-cell proliferation. We screened 168 patients with MM and found that CD86 and human leukocyte antigen G (HLA-G) were antigens commonly acquired by T cells from malignant plasma cells. CD3 +CD86acq+ and CD3+ HLA-Gacq+ cells were more prevalent in bone marrow than peripheral blood samples. The presence of either CD86 or HLA-G on malignant plasma cells was associated with a poor prognosis. CD38++ side population cells expressed HLA-G, suggesting that these putative myeloma stem cells could generate immune tolerance. HLA-G+ T cells had a regulatory potency similar to natural Tregs, thus providing another novel mechanism for MM to avoid effective immune surveillance. © 2012 by The American Society of Hematology.
Please use this identifier to cite or link to this item: